Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEVG.L Regulatory News (EVG)

  • There is currently no data for EVG

Statement re Evolution (Disclosure under Rule 2.11d)

19 Sep 2011 11:17

ABERFORTH PARTNERS LLP

Disclosure under Rule 2.11 of the City Code on Takeovers and Mergers

Aberforth Partners LLP ("Aberforth") provided a non-binding letter of intent to Investec plc regarding Investec's plc's proposed acquisition of Evolution Group plc ("Evolution"), as referred to in the announcement of the Recommended Share Offer dated 9 September 2011. On 16 September 2011, Aberforth disposed of 896,567 shares (over which it had voting authority) in Evolution, on behalf of clients. As a result, Aberforth now intends to vote in favour of the resolutions to be proposed at the Court Meeting and the Evolution general meeting necessary to approve the Scheme (or as the case may be, to accept the Takeover Offer) in respect of 14,436,777 Evolution shares, over which it has voting authority.

Aberforth Partners LLP

19 September 2011

XLON
Date   Source Headline
22nd Mar 20217:00 amRNSAppointment of Chief Business Officer
15th Mar 20219:00 amRNSHolding(s) in Company
11th Mar 20217:00 amRNSUpdate on Data Safety Review - STAR COVID-19 trial
9th Mar 202111:35 amRNSHolding(s) in Company
8th Mar 20211:49 pmRNSHolding(s) in Company
5th Mar 20214:04 pmRNSHolding(s) in Company
5th Mar 20219:17 amRNSDirector dealing
3rd Mar 202112:10 pmRNSResult of General Meeting & Total Voting Rights
3rd Mar 20217:00 amRNSResult of Open Offer
26th Feb 20214:39 pmRNSHolding(s) in Company
17th Feb 20219:58 amRNSHolding(s) in Company
17th Feb 20217:00 amRNSUpdate on patient recruitment
12th Feb 20217:00 amRNSPosting of Circular & Notice of GM
2nd Feb 20213:15 pmRNSPlacing and Open Offer to raise up to £11 million
22nd Jan 20217:00 amRNSPreclinical data on a new therapeutic target
21st Jan 20217:00 amRNSPositive pre-clinical data for lead asset SFX-01
19th Jan 20217:00 amRNSPatient recruitment update in STAR-COVID 19 trial
23rd Dec 20202:05 pmRNSSecond Price Monitoring Extn
23rd Dec 20202:00 pmRNSPrice Monitoring Extension
10th Dec 20207:00 amRNSHalf-year Report
27th Nov 20202:33 pmRNSHolding(s) in Company
27th Nov 20209:15 amRNSHolding(s) in Company
23rd Nov 20207:00 amRNSRecruitment of first patient in STAR trial
11th Nov 20207:00 amRNSComment on the COVID-19 vaccine announcement
6th Nov 20209:25 amRNSHolding(s) in Company
29th Oct 202011:55 amRNSHolding(s) in Company
29th Oct 20209:09 amRNSHolding(s) in Company
26th Oct 20203:00 pmRNSHolding(s) in Company
23rd Oct 20207:00 amRNSAll approvals received for STAR trial to commence
6th Oct 20207:00 amRNSGrant of options
24th Sep 20207:00 amRNSAppointment of Chief Executive Officer
15th Sep 20207:00 amRNSLicence agreement with Juvenescence
18th Aug 20203:30 pmRNSHolding(s) in Company
18th Aug 20203:25 pmRNSHolding(s) in Company
14th Aug 20204:41 pmRNSSecond Price Monitoring Extn
14th Aug 20204:35 pmRNSPrice Monitoring Extension
5th Aug 20204:41 pmRNSSecond Price Monitoring Extn
5th Aug 20204:35 pmRNSPrice Monitoring Extension
31st Jul 20203:40 pmRNSHolding(s) in Company
24th Jul 20209:47 amRNSShare option exercise and issue of equity
17th Jul 202012:05 pmRNSHolding(s) in Company
17th Jul 202012:02 pmRNSHolding(s) in Company
16th Jul 20202:52 pmRNSResult of AGM
7th Jul 202011:13 amRNSShare option exercise and issue of equity
6th Jul 20207:00 amRNSShare option exercise and issue of equity
23rd Jun 202011:44 amRNSHolding(s) in Company
23rd Jun 202011:38 amRNSHolding(s) in Company
19th Jun 20207:00 amRNSNotice of AGM
17th Jun 20209:38 amRNSHolding(s) in Company
17th Jun 20209:37 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.